teaser
A new disposable insulin injection pen for people with type 1 and type 2 diabetes has won a design award from the Chicago Athenaeum Museum of Architecture and Design.
SoloSTAR, which is manufactured by pharmaceutical firm Sanofi-Aventis, aids administration of Lantus and Apidra, which are the branded names of insulin glargine, and allows patients to receive an appropriate dose in one injection.
It can dispense doses of up to 80 units, and uses a simple system with an easy-to-read display, which means it requires only a few steps to use it properly.
The device for both branded insulin substances was approved by the European Medicines Agency (EMEA) in September 2006, while Lantus SoloSTAR was granted approval by the Food and Drug Administration in the US in April last year.
Christian Narkiewicz-Laine, president of the museum, said: “SoloSTAR is a marriage of sleek, handsome design styling with easy, but advanced sophisticated technology for dispensing insulin to people with diabetes.
“SoloSTAR represents a design for social good and for humanitarian concerns.”
Denis Raccah, professor of endocrinology at the University Hospital Sainte Marguerite in France, added: “Insulin injection with SoloSTAR brings flexibility, satisfaction for the patients, and an opportunity for earlier initiation of insulin therapy which may contribute to better long-term glycaemic control.”
Copyright © PA Business 2008
